Flutamide

Androgen Receptor Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Flutamide is an ofp drug in the Androgen Receptor Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1989. Its mechanism of action is classified as Androgen Receptor Antagonists. DrugCentral lists 6 molecular targets, including AR, HTR4 and CYP1A2. Recorded indications include Neoplasm of prostate.

• Approval status: ofp (first approved 1989 by the FDA).
• Drug class: Androgen Receptor Inhibitor.
• Mechanism of action: Androgen Receptor Antagonists.
• Molecular targets: AR, HTR4, CYP1A2 and HTR6 (6 listed in DrugCentral).
• Indications: Neoplasm of prostate.
• ATC code: L02BB01 (Anti-androgens).
• Molecular formula: C11H11F3N2O3; molecular weight 276.21 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Neoplasm of prostate

Contraindications (9)

• Anemia due to enzyme deficiency
• Breastfeeding (mother)
• Deficiency of cytochrome-b>5< reductase
• Deficiency of glucose-6-phosphate dehydrogenase
• Disease of liver
• Hepatic failure
• Hyperbilirubinemia
• Methemoglobinemia
• Pregnancy, function

Mechanism & targets

• Mechanism of action (MoA): Androgen Receptor Antagonists
• Established pharmacologic class: Androgen Receptor Inhibitor

Molecular targets (6)

Target	Gene	Action	Activity
Androgen receptor	AR	antagonist	Ki 5.89
5-hydroxytryptamine receptor 4	HTR4	unknown	Ki 5.65
Cytochrome P450 1A2	CYP1A2	unknown	Ki 5.36
5-hydroxytryptamine receptor 6	HTR6	unknown	Ki 5.08
Androgen receptor	Ar	unknown	Ki 5.05
Bile salt export pump	Abcb11	unknown	IC50 4.10

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1989-01-27	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
L02BB01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ENDOCRINE THERAPY › HORMONE ANTAGONISTS AND RELATED AGENTS › Anti-androgens

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: G6PD · Actionable PGx
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Prostatic specific antigen increased	202.3
Osteonecrosis of jaw	124.0
Hormone-refractory prostate cancer	71.9
Prostate cancer	68.7
Metastases to bone	67.1
Bladder tamponade	49.8
Interstitial lung disease	44.4
Malignant neoplasm progression	30.0
Nephropathy	29.9
Anaemia	28.9
Granulomatosis with polyangiitis	28.3
Prostate cancer metastatic	26.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Flutamide is on its molecule page.

• Molecular formula: C₁₁H₁₁F₃N₂O₃
• Molecular weight: 276.21 g/mol
• CAS number: 13311-84-7
• InChIKey: MKXKFYHWDHIYRV-UHFFFAOYSA-N
• PubChem CID: 3397

CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Flutamide used for?

DrugCentral lists the following indications for Flutamide: Neoplasm of prostate.

How does Flutamide work?

Flutamide is classified as Androgen Receptor Antagonists; its molecular targets in DrugCentral include AR (antagonist), HTR4, CYP1A2 and HTR6.

When was Flutamide first approved?

Flutamide was first approved by the FDA in 1989.

What drug class does Flutamide belong to?

Flutamide is in the Androgen Receptor Inhibitor class.

What is the chemical formula of Flutamide?

Flutamide has the molecular formula C11H11F3N2O3 and a molecular weight of 276.21 g/mol.

Sources

• DrugCentral drug card 1223 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL806 — compound record and bioactivity
• PubChem CID 3397 — chemical identifiers
• DrugBank DB00499 — drug record
• FDA UNII 76W6J0943E — substance identity
• DailyMed: FDA labels for Flutamide — current prescribing information (label search)
• UniProt P10275 (AR) — target protein
• UniProt P05177 (CYP1A2) — target protein
• UniProt P50406 (HTR6) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.